Cannabis

Cannabis: Currently Approved Indications and Therapeutic Potential

Dr. Paul Morrison Clinical Senior Lecturer Institute of Psychiatry King’s College London NHS Consultant Psychiatrist The Maudsley Hospital, London       This presentation reviews indications for currently approved cannabis products (dronabinol and nabilone). It also discusses the therapeutic potential of CBD in psychiatry (psychosis) and other medical conditions (epilepsy, oncology). In this section, we’ll…

Read More

Understanding Cannabis in Psychiatry: Pharmacology and Synthetic Cannabinoids

Dr. Paul Morrison   Clinical Senior Lecturer Institute of Psychiatry King’s College London   NHS Consultant Psychiatrist The Maudsley Hospital, London     This presentation discusses cannabinoid pharmacology and synthetic cannabinoids. The endocannabinoid system consists of: CB1 and CB2 receptors, anandamide, 2‐arachidonoylglycerol (2-AG). Regarding synthetic cannabinoids, they are CB1 full agonists and their effect is…

Read More

Cannabis and Mental Health: 2017 Report of the National Academy of Sciences, Engineering and Medicine

Author: Flavio Guzman, MD The National Academies of Sciences, Engineering, and Medicine published a report on the health effects of cannabis and cannabinoids. Here we reproduce the key points of the mental health chapter. You can access the full publication here. Psychosis and schizophrenia Cannabis use is likely to increase the risk of developing schizophrenia…

Read More